200 related articles for article (PubMed ID: 35597867)
1. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells.
Zhou G; Lieshout R; van Tienderen GS; de Ruiter V; van Royen ME; Boor PPC; Magré L; Desai J; Köten K; Kan YY; Ge Z; Campos Carrascosa L; Geuijen C; Sprengers D; van der Laan LJW; Verstegen MMA; Kwekkeboom J
Br J Cancer; 2022 Sep; 127(4):649-660. PubMed ID: 35597867
[TBL] [Abstract][Full Text] [Related]
2. Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids.
Amato F; Rae C; Prete MG; Braconi C
Cells; 2020 Mar; 9(4):. PubMed ID: 32235647
[TBL] [Abstract][Full Text] [Related]
3. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
[TBL] [Abstract][Full Text] [Related]
4. Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
Koch M; Nickel S; Lieshout R; Lissek SM; Leskova M; van der Laan LJW; Verstegen MMA; Christ B; Pampaloni F
Cells; 2022 Nov; 11(22):. PubMed ID: 36429040
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.
Fujiwara H; Takahara N; Tateishi K; Tanaka M; Kanai S; Kato H; Nakatsuka T; Yamamoto K; Kogure H; Arita J; Nakai Y; Kasuga M; Ushiku T; Hasegawa K; Koike K
Surg Oncol; 2020 Dec; 35():484-490. PubMed ID: 33126085
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
Vatankhah F; Salimi N; Khalaji A; Baradaran B
Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
[TBL] [Abstract][Full Text] [Related]
9. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
[TBL] [Abstract][Full Text] [Related]
11. The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients.
Kida A; Mizukoshi E; Kido H; Toyama T; Terashima T; Arai K; Yamashita T; Fushimi K; Yamashita T; Sakai Y; Honda M; Uchiyama A; Sakai A; Shimizu K; Kaneko S
Hepatol Int; 2021 Jun; 15(3):695-706. PubMed ID: 33754279
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions.
Massani M; Stecca T; Fabris L; Caratozzolo E; Ruffolo C; Furlanetto A; Morton S; Cadamuro M; Strazzabosco M; Bassi N
Oncol Rep; 2013 Sep; 30(3):1143-8. PubMed ID: 23807641
[TBL] [Abstract][Full Text] [Related]
13. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
De Siervi S; Turato C
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
15. Serum markers of intrahepatic cholangiocarcinoma.
Malaguarnera G; Paladina I; Giordano M; Malaguarnera M; Bertino G; Berretta M
Dis Markers; 2013; 34(4):219-28. PubMed ID: 23396291
[TBL] [Abstract][Full Text] [Related]
16. [Establishment and application of intrahepatic cholangiocarcinoma organoid models].
Liu Y; Liang X
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):346-352. PubMed ID: 38432677
[TBL] [Abstract][Full Text] [Related]
17. Anti-Proliferative Effects of Compound A and Its Effect in Combination with Cisplatin in Cholangiocarcinoma Cells.
Junking M; Rattanaburee T; Panya A; Budunova I; Haegeman G; Yenchitsomanus PT
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2673-2681. PubMed ID: 32986368
[TBL] [Abstract][Full Text] [Related]
18. Targeting PDGFR-β in Cholangiocarcinoma.
Fingas CD; Mertens JC; Razumilava N; Bronk SF; Sirica AE; Gores GJ
Liver Int; 2012 Mar; 32(3):400-9. PubMed ID: 22133064
[TBL] [Abstract][Full Text] [Related]
19. Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system.
Saito Y; Nakaoka T; Muramatsu T; Ojima H; Sukeda A; Sugiyama Y; Uchida R; Furukawa R; Kitahara A; Sato T; Kanai Y; Saito H
Sci Rep; 2018 Feb; 8(1):2821. PubMed ID: 29434290
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
